

SPECIAL FEATURES

CCR Pediatric Oncology Series

Complimentary access to this online-only series of articles from the AACR Childhood Cancer Predisposition Workshop:
clincancerres.aacrjournals.org/pediatricseries

- e133** **The Future of Surveillance in the Context of Cancer Predisposition: Through the Murky Looking Glass**
David Malkin, Kim E. Nichols, Joshua D. Schiffman, Sharon E. Plon, and Garrett M. Brodeur

Highlights of This Issue 6379

CCR Translations

- 6381** **Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far from the Tree**
Paulo Bergerot, Neeraj Agarwal, Sumanta K. Pal, and Jeremy Jones
See related article, p. 6686

CCR Drug Updates

- 6384** **FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen**
Christy L. Osgood, Meredith K. Chuk, Marc R. Theoret, Lan Huang, Kun He, Leah Her, Patricia Keegan, and Richard Pazdur

Molecular Pathways

- 6390** **Molecular Pathways: Targeting the Microenvironment of Liver Metastases**
Simon Milette, Jason K. Sicklick, Andrew M. Lowy, and Pnina Brodt

CANCER THERAPY: CLINICAL

- 6400** **Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors**
Mallika S. Dhawan, Imke H. Bartelink, Rahul Raj Aggarwal, Jim Leng, Jenna Z. Zhang, Nela Pawlowska, Manuela Terranova-Barberio, Jennifer A. Grabowsky, Andrew Gewitz, Amy J. Chien, Mark Moasser, Robin K. Kelley, Tayeba Maktabi, Scott Thomas, and Pamela N. Munster

- 6411** **Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies**
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Marie Maerevoet, Jean-Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, Jean-Marie Michot, Karen Silence, Anna Hultberg, Domenica Gandini, Hans de Haard, Vincent Ribrag, Marc Peeters, Alain Thibault, Nicolas Leupin, and Ahmad Awada

- 6421** **Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies**
Shailey Mehrotra, Mathangi Gopalakrishnan, Jogarao Gobburu, Jiuping Ji, Jacqueline M. Greer, Richard Piekarz, Judith E. Karp, Keith W. Pratz, and Michelle A. Rudek

- 6430** **Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature**
Charles F. Craddock, Aimee E. Houlton, Lynn Swun Quek, Paul Ferguson, Emma Gbandi, Corran Roberts, Marlen Metzner, Natalia Garcia-Martin, Alison Kennedy, Angela Hamblin, Manoj Raghavan, Sandeep Nagra, Louise Dudley, Keith Wheatley, Mary Frances McMullin, Srinivas P. Pillai, Richard J. Kelly, Shamyla Siddique, Michael Dennis, Jamie D. Cavenagh, and Paresh Vyas

- 6441** **A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma**
Sara M. Federico, M. Beth McCarville, Barry L. Shulkin, Paul M. Sondel, Jacquelyn A. Hank, Paul Hutson, Michael Meagher, Aaron Shafer, Catherine Y. Ng, Wing Leung, William E. Janssen, Jianrong Wu, Shenghua Mao, Rachel C. Brennan, Victor M. Santana, Alberto S. Pappo, and Wayne L. Furman

- 6450** **Underreporting of Research Biopsies from Clinical Trials in Oncology**
Christine M. Parseghian, Kanwal Raghav, Robert A. Wolff, Joe Ensor Jr, James Yao, Lee M. Ellis, Alda L. Tam, and Michael J. Overman



Table of Contents

PERSONALIZED MEDICINE AND IMAGING

6458 Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment

Elena Martínez-García, Antoine Lesur, Laura Devis, Silvia Cabrera, Xavier Matias-Guiu, Marc Hirschfeld, Jasmin Asberger, Jan van Oostrum, María de los Ángeles Casares de Cal, Antonio Gómez-Tato, Jaume Reventos, Bruno Domon, Eva Colas, and Antonio Gil-Moreno

6468 A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors

Kurt W. Evans, Erkan Yuca, Argun Akcakanat, Stephen M. Scott, Natalia Paez Arango, Xiaofeng Zheng, Ken Chen, Coya Tapia, Emily Tarco, Agda K. Eterovic, Dalliah M. Black, Jennifer K. Litton, Timothy A. Yap, Debu Tripathy, Gordon B. Mills, and Funda Meric-Bernstam

6478 An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia

Roni Shouval, Annalisa Ruggeri, Myriam Labopin, Mohamad Mohty, Guillermo Sanz, Gerard Michel, Jürgen Kuball, Patrice Chevallier, Amal Al-Seraihy, Noel-Jean Milpied, Cristina Diaz de Heredia, William Arcese, Didier Blaise, Vanderson Rocha, Joshua Fein, Ron Unger, Frederic Baron, Peter Bader, Eliane Gluckman, and Arnon Nagler

6487 Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer



Gillian Vandekerckhove, Tilman Todenhöfer, Matti Annala, Werner J. Struss, Amanda Wong, Kevin Beja, Elie Ritch, Sonal Brahmbhatt, Stanislav V. Volik, Jörg Hennenlotter, Matti Nykter, Kim N. Chi, Scott North, Arnulf Stenzl, Colin C. Collins, Bernhard J. Eigl, Peter C. Black, and Alexander W. Wyatt

6498 ⁸⁹Zr-anti-γH2AX-TAT but not ¹⁸F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma

James C. Knight, Michael J. Mosley, Luisa Contreras Bravo, Veerle Kersemans, P. Danny Allen, Somnath Mukherjee, Eric O'Neill, and Bart Cornelissen

6505 Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER⁺/HER2⁻ Breast Cancer

Bas H.M. van der Velden, Sjoerd G. Elias, Tycho Bismeyer, Claudette E. Loo, Max A. Viergever, Lodewyk F.A. Wessels, and Kenneth G.A. Gilhuijs

CANCER THERAPY: PRECLINICAL

6516 Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer

Jin Liu, Mikael Agopiantz, Joël Poupon, Zherui Wu, Pierre-Alexandre Just, Bruno Borghese, Evelyne Ségal-Bendirdjian, Guillaume Gauchotte, Anne Gompel, and Patricia Forgez

6529 Targeting RNA-Polymerase I in Both Chemosensitive and Chemosistant Populations in Epithelial Ovarian Cancer

Robert Cornelison, Zachary C. Dobbin, Ashwini A. Katre, Dae Hoon Jeong, Yinfeng Zhang, Dongquan Chen, Yuliya Petrova, Danielle C. Llana, Adam D. Steg, Laura Parsons, David A. Schneider, and Charles N. Landen

6541 Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation



Noriaki Tanaka, Ameeta A. Patel, Lin Tang, Natalie L. Silver, Antje Lindemann, Hideaki Takahashi, Roman Jaksik, Xiayu Rao, Nene N. Kalu, Tseng-Cheng Chen, Jiping Wang, Mitchell J. Frederick, Faye Johnson, Frederico O. Gleber-Netto, Siqing Fu, Marek Kimmel, Jing Wang, Walter N. Hittelman, Curtis R. Pickering, Jeffrey N. Myers, and Abdullah A. Osman

6555 *In Vivo* Validation of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target



Ada W.Y. Leung, Chansey J. Veinotte, Nicole Melong, Min Hee Oh, Kent Chen, Katey S.S. Enfield, Ian Backstrom, Corinna Warburton, Donald Yapp, Jason N. Berman, Marcel B. Bally, and William W. Lockwood

6567 Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation

Puyu Shi, You-Take Oh, Liang Deng, Guojing Zhang, Guoqing Qian, Shuo Zhang, Hui Ren, Grant Wu, Benjamin Legendre, JrEmily Anderson, Suresh S. Ramalingam, Taofeek K. Owonikoko, Mingwei Chen, and Shi-Yong Sun

Table of Contents

6580 The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Shu-Xiong Zeng, Yanjun Zhu, Ai-Hong Ma, Weimin Yu, Hongyong Zhang, Tzu-Yin Lin, Wei Shi, Clifford G. Tepper, Paul T. Henderson, Susan Airhart, Jian-Ming Guo, Chuan-Liang Xu, Ralph W. deVere White, and Chong-Xian Pan

6592 Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer
Max Kates, Abhijit Date, Takahiro Yoshida, Umara Afzal, Pranjali Kanvinde, Taarika Babu, Nikolai A. Sopko, Hotaka Matsui, Noah M. Hahn, David J. McConkey, Alexander Baras, Justin Hanes, Laura Ensign, and Trinity J. Bivalacqua

6602 Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma
Elizabeth A. Rojas, Luis Antonio Corchete, Laura San-Segundo, Juan F. Martínez-Blanch, Francisco M. Codoñer, Teresa Paño, Noemí Puig, Ramón García-Sanz, María Victoria Mateos, Enrique M. Ocio, Irena Misiewicz-Krzeminska, and Norma C. Gutiérrez

6616 ¹³¹I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
Matthias D'Huyvetter, Jens De Vos, Catarina Xavier, Marek Pruszynski, Yann G.J. Sterckx, Sam Massa, Geert Raes, Vicky Caveliers, Michael R. Zalutsky, Tony Lahoutte, and Nick Devoogdt

BIOLOGY OF HUMAN TUMORS

6629 p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Myrthala Moreno-Smith, Anna Lakoma, Zaowen Chen, Ling Tao, Kathleen A. Scorsone, Linda Schild, Kevin Aviles-Padilla, Rana Nikzad, Yankai Zhang, Rikhia Chakraborty, Jan J. Molenaar, Sanjeev A. Vasudevan, Vivien Sheehan, Eugene S. Kim, Silke Paust, Jason M. Shohet, and Eveline Barbieri

6640 Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/ β -Catenin Signaling
Guangzhi Wang, Jia Shen, Jiahang Sun, Zhenfeng Jiang, Jiabing Fan, Hongjun Wang, Shan Yu, Yu Long, Yi Liu, Hongbo Bao, Kelvin Xi Zhang, Ke Han, Minwei Zhu, Yongri Zheng, Zhiguo Lin, Chuanlu Jiang, and Mian Guo

6650 Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival
Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Meijing Wu, Matthew Genet, Galina Gritsina, Balázs Gyórfy, Priscilla K. Brastianos, David C. Binder, Jeffrey A. Sosman, Francis J. Giles, Charles D. James, Craig Horbinski, Roger Stupp, and Derek A. Wainwright

6661 Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring *MET* Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D. Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A. Tovar, Curt J. Essenburg, Zachary Madaj, Harrah Chiang, David Briere, Jill Hallin, Pedro P. Lopez-Casas, Natalia Baños, Camino Menendez, Manuel Hidalgo, Vanessa Tassell, Richard Chao, Darya I. Chudova, Richard B. Lanman, Peter Olson, Lyudmilla Bazhenova, Sandip Pravin Patel, Carrie Graveel, Mizuki Nishino, Geoffrey I. Shapiro, Nir Peled, Mark M. Awad, Pasi A. Jänne, and James G. Christensen

6673 The KMT1A-GATA3-STAT3 Circuit Is a Novel Self-Renewal Signaling of Human Bladder Cancer Stem Cells
Zhao Yang, Luyun He, Kaisu Lin, Yun Zhang, Aihua Deng, Yong Liang, Chong Li, and Tingyi Wen

6686 Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape
Zixing Wang, Tae Beom Kim, Bo Peng, Jose Karam, Chad Creighton, Aron Joon, Fumi Kawakami, Patricia Trevisan, Eric Jonasch, Chi-Wan Chow, Jaime Rodriguez Canales, Pheroze Tamboli, Nizar Tannir, Christopher Wood, Federico Monzon, Keith Baggerly, Marileila Varella-Garcia, Bogdan Czerniak, Ignacio Wistuba, Gordon Mills, Kenna Shaw, Ken Chen, and Kanishka Sircar
See related commentary, p. 6381

6697 Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Anna Kreutzman, Beatriz Colom-Fernández, Ana Marcos Jiménez, Mette Ilander, Carlos Cuesta-Mateos, Yaiza Pérez-García, Cristina Delgado Arévalo, Oscar Brück, Henna Hakonen, Jani Saarela, Alvaro Ortega-Carrión, Ana de Rosendo, Alba Juanes-García, Juan Luis Steegmann, Satu Mustjoki, Miguel Vicente-Manzanares, and Cecilia Muñoz-Calleja



Table of Contents

6708 Diverse *BRCA1* and *BRCA2* Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, Lei Tian, Jane L. Meisel, Isaac García-Murillas, Charlotte Fribbens, Ros Cutts, Luciano G. Martelotto, Charlotte K.Y. Ng, Raymond S. Lim, Pier Selenica, Salvatore Piscuoglio, Carol Aghajanian, Larry Norton, Rajmohan Murali, David M. Hyman, Laetitia Borsu, Maria E. Arcila, Jason Konner, Jorge S. Reis-Filho, Roger A. Greenberg, Mark E. Robson, and Nicholas C. Turner

6721 Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and *MUTYH*-associated Polyposis

Laura E. Thomas, Joanna J. Hurley, Elena Meuser, Sian Jose, Kevin E. Ashelford, Matthew Mort, Shelley Idziaszczyk, Julie Maynard, Helena Leon Brito, Manon Harry, Angharad Walters, Meera Raja, Sarah-Jane Walton, Sunil Dolwani, Geraint T. Williams, Meleri Morgan, Morgan Moorghen, Susan K. Clark, and Julian R. Sampson

6733 Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance

Amber E. Bannon, Jason Kent, Isaac Forquer, Ajia Town, Lillian R. Klug, Kelly McCann, Carol Beadling, Oliver Harismendy, Jason K. Sicklick, Christopher Corless, Ujwal Shinde, and Michael C. Heinrich

6744 *Numb*^{-/low} Enriches a Castration-Resistant Prostate Cancer Cell Subpopulation Associated with Enhanced Notch and Hedgehog Signaling


Yanjing Guo, Kai Zhang, Chaping Cheng, Zhongzhong Ji, Xue Wang, Minglei Wang, Mingliang Chu, Dean G. Tang, Helen He Zhu, and Wei-Qiang Gao

 AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a section of low-grade serous ovarian carcinoma. Inhibition of neurotensin receptor 1 in ovarian cancer is correlated with higher carboplatin response. For details, see the article by Liu and colleagues on page 6516 of this issue.



Clinical Cancer Research

23 (21)

Clin Cancer Res 2017;23:e133-6756.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/23/21>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/23/21>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.